Psoriasis Drug Market Analysis, Size, Share & Growth Forecast 2026–2034

Bimekizumab BE SURE 86 Percent PASI 100 Complete Skin Clearance and 85 to 91 Percent PASI 90 Head-to-Head Versus Secukinumab 74 Percent and Adalimumab 47 Percent PASI 90 Has Established Dual IL-17A and IL-17F Blockade as the Most Effective Plaque Psoriasis Biologic.AbbVie's risankizumab PASI-100 response of 56% at 52 weeks versus secukinumab's 47% and IL-17A inhibitors' 35-40% represents the highest complete skin clearance rate reported in any 52-week Phase 3 psoriasis trial, establishing p19-selective IL-23 inhibition as the most potent psoriasis mechanism available. The PASI-100 endpoint representing completely clear skin has become the commercial differentiation benchmark in psoriasis, replacing PASI-75 as the primary marketing claim as the absolute proportion of clear-skin achievers differentiates IL-23 p19 inhibitors from IL-17A and TNF inhibitors that rarely achieve complete clearance in more than 35-40% of patients. Commercial marketing of PASI-100 rates has shifted prescriber expectations about the achievable outcome in psoriasis, and patient advocacy groups are incorporating complete clearance as the treatment goal that healthcare systems should support rather than the partial improvement that prior standards accepted.

Risankizumab Skyrizi IL-23 p19 Selective Inhibitor 72 to 75 Percent PASI 90 at 52 Weeks With Quarterly Dosing After Induction Has Positioned the IL-23 Selective Mechanism as the Most Effective and Convenient Biologic for Moderate-to-Severe Psoriasis Versus Monthly IL-17 Inhibitor Injection.Bristol-Myers Squibb's deucravacitinib Sotyktu demonstrated 58.7% PASI-75 response versus 35.1% for apremilast and 35.1% for placebo in POETYK PSO-1 at 16 weeks, positioning the TYK2 allosteric inhibitor as a superior oral alternative to apremilast that approaches subcutaneous IL-17 class efficacy in a daily tablet. The pseudokinase domain binding mechanism of deucravacitinib selectively inhibits TYK2 regulatory function without binding JAK1, JAK2, or JAK3 catalytic sites, achieving IL-23 and type I interferon signalling blockade without the cardiovascular and malignancy labelling that limits JAK1 inhibitors in patients over 50 with cardiovascular risk factors. Real-world deucravacitinib prescribing data from the first two years of commercial launch shows it capturing approximately 30% of new oral systemic psoriasis prescriptions, reflecting meaningful physician adoption of the superior oral option versus the established but lower-efficacy apremilast standard.

Deucravacitinib Sotyktu TYK2 Inhibitor POETYK 53 Percent PASI 75 Versus 35 Percent Apremilast Has Established the Oral TYK2 Mechanism as the Superior Oral Targeted Therapy for Moderate Psoriasis That Apremilast's Lower Efficacy Cannot Match.IxPlore long-term extension of ixekizumab showing 73% PASI-75 maintenance at 5 years and Cosentyx secukinumab SCULPTURE data demonstrating sustained PASI-90 above 75% at 5 years establish that IL-17A inhibition produces durable psoriasis control without the secondary failure that characterises TNF inhibitors where anti-drug antibody development reduces long-term efficacy in approximately 20-30% of patients. The immunogenicity advantage of IL-17 and IL-23 inhibitors over TNF inhibitors reflects the lower immunogenic potential of fully human antibodies compared with chimeric or humanised TNF inhibitors, and long-term survival analyses consistently show superior drug survival for IL-17 and IL-23 class agents versus adalimumab in real-world registries. Biologic switching patterns in psoriasis registries confirm that patients who fail an IL-17A inhibitor have approximately 50% response rates on switching to a different IL-17A inhibitor and above 60% response rates on switching to an IL-23 inhibitor, guiding sequential biologic prescribing decisions in psoriasis.

For related market intelligence, see the Immunology Drug Market.